Growth inhibition observed following administration of an LHRH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle
- 1 December 1991
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 63 (6) , 930-932
- https://doi.org/10.1038/bjc.1991.203
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Characteristics and distribution of receptors for [d‐trp6]‐ luteinizing hormone‐releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancerJournal of Clinical Laboratory Analysis, 1989
- A DIRECT LHRH-AGONIST ACTION ON CANCER-CELLS IS UNLIKELY TO BE THE CAUSE OF RESPONSE TO LHRH-AGONIST TREATMENT1989
- GROWTH INHIBITORY EFFECT OF LH-RH ANALOGS ON HUMAN-BREAST CANCER-CELLS1988
- 3Clinical applications of LHRH analoguesBailliere's Clinical Endocrinology and Metabolism, 1987
- Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630British Journal of Cancer, 1986
- Preliminary endocrinological evaluation of a sustained-release formulation of the LH-releasing hormone agonist d-Ser(But)6Azgly10LHRH in premenopausal women with advanced breast cancerJournal of Endocrinology, 1986
- The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancerBritish Journal of Cancer, 1986
- Treatment of Breast Cancer with Gonadotropin-Releasing HormoneEndocrine Reviews, 1986
- Gonadotropin-Releasing Hormone Binding Sites in Human Breast CarcinomaScience, 1985
- A new class of contraceptives?Nature, 1982